Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Janux Therapeutics is a biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary TRACTr and TRACIr platforms create bispecific biologics designed to target solid tumors with enhanced safety, reduced toxicity, and extended half-life. Focused on cancers like prostate, colorectal, and lung, the company aims to deliver off-the-shelf, tumor-specific treatments that activate immune responses precisely within the tumor microenvironment.
This description was generated via AI from an annual report. Updated about 1 year ago.